After six years of continuous data collection, TG Therapeutics Inc. (TGTX) is entering a new phase of refinement. The company's momentum in 2025 is shaped not just by clinical progress, but by a sharpened focus on patient experience and dosing innovation.
With updated long-term results for BRIUMVI and a completed Phase 3 enrollment for a streamlined regimen, TG Therapeutics is laying the groundwork for what could be its next chapter in multiple sclerosis care.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.